PHILADELPHIA, April 07, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s long-term investors.
Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/
Since December 2023, shares of Amicus’ common stock have declined in value from a trading price of $14.50 per share to a current trading price of below $8.00 per share, a decline of nearly 45% in value.
The investigation seeks to determine whether Amicus and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to investors in connection with recent corporate actions.
Amicus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, or by clicking on the following link (or by copying and pasting the link into your browser):
https://kaskelalaw.com/case/amicus-therapeutics/
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.